title: Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs.
abstract: BACKGROUND
  Acetaminophen (paracetamol-P) is a widely used analgesic-antipyretic drug with no anti inflammatory effects and its rate of adverse hypersensitivity reactions is very low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in side effects. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.
  
  
  OBJECTIVE
  We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and to classic NSAIDs.
  
  
  METHODS
  We studied 29 patients with hypersensitivity to P and classic NSAIDs. The diagnosis of P-induced skin reactions was based on in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses was given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and they were controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rash or urticaria-angioedema.
  
  
  RESULTS
  No reaction was observed with placebo and twenty eight patients (96.5 %) tolerated CE. Only one patient developed a moderate angioedema of the lips.
  
  
  CONCLUSIONS
  Only one hypersensitivity reaction to CE was documented among 29 P-intolerant patients. Thus, we conclude that CE is a reasonably safe alternative which can be used in subjects who do not tolerate P.
authors.affiliation: Department of Chest Diseases, Division of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy. gennaro.liccardi@tin.it
authors.forename: G
authors.initials: G
authors.lastname: Liccardi
authors.forename: M
authors.initials: M
authors.lastname: Cazzola
authors.forename: C
authors.initials: C
authors.lastname: De Giglio
authors.forename: D
authors.initials: D
authors.lastname: Manfredi
authors.forename: E
authors.initials: E
authors.lastname: Piscitelli
authors.forename: M
authors.initials: M
authors.lastname: D'Amato
authors.forename: G
authors.initials: G
authors.lastname: D'Amato
mesh_terms: D000082:Acetaminophen / Q000009:adverse effects*; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology*; D016037:Single-Blind Method; D012871:Skin Diseases / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000082:Acetaminophen; D000068579:Celecoxib